Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: an internal examination of venture capital

This article was originally published in Scrip

Executive Summary

These are comparatively uncomfortable times for life science venture capital (VC) investors. In the 1990s, VCs could bring a life science company to the public markets, recover their cost by divesting part of their investment at the IPO, and see their remaining holding rocket in value as generalist shareholders clamoured for the next hot biotech biotechnology IPO. A few months after the IPO, and with a little luck, many companies were also able to complete secondary offerings of stock from their VCs, CEOs and CFOs, putting most of the company’s shares in public hands.

You may also be interested in...



Stockwatch: Pandemic And Biosimilar Effects Subordinate Early Third-Quarter Earnings Results

Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.

Stockwatch: Some Failed Drugs Never Die, They Just Find New Investors

Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.

Stockwatch: Batsu Games − Drug And Vaccine Development

Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.

Topics

Related Companies

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel